EastHORN has an extensive background in infectious diseases. The majority of the studies have been in Phases II and III. Areas of particular strength are:
- Aspergillosis
- Bacterial Complications in Cystic Fibrosis
- Bacterial Vaginosis
- Candidiasis
- COVID-19 Vaccine
- Community Acquired Pneumonia
- Cytomegalovirus (CMV) infection
- Hepatitis B
- Hepatitis C
- HIV
- Hospital Acquired Pneumonia
- Human Papilloma Virus
- Influenza
- Intra-abdominal Infections
- Mild or Moderate COVID-19
- Meningitis
- MRSA infection
- Osteomyelitis
- Pneumonia (HAP/CAP)
- Skin and Soft Tissue Infections
- Tuberculosis
- Urinary Track Infections
- Viral rhinitis
EastHORN has experience in the following categories of anti-infective agents:
- Interferons
- Protease Inhibitors
- Vaccines
- Antibiotics
- Hospital acquired infection control